Search | IOVS | ARVO Journals

Showing 1 – 20 of 39

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

Retina December 2024

Clinically Meaningful Change Estimates for the National Eye Institute Visual Function Questionnaire-25 in Patients With Diabetic Macular Edema

PDF

Neil Bressler; Zdenka Haskova; Audrey Kapre; Brittany Gentile
TAGS: diabetic macular edema, eye, questionnaires, vision, visual acuity
Trans. Vis. Sci. Tech.. 2024; 13(12):27. https://doi.org/10.1167/tvst.13.12.27

Includes: Supplemental Content

ARVO Annual Meeting Abstract June 2024

Intravitreal interleukin-6 inhibition with vamikibart in sarcoidosis-associated uveitis

Meike Pauly-Evers; Zeinab Barekati; Federica Storti; William Holmes; Laura Steeples; Zdenka Haskova; Phoebe Lin; Sumit Sharma; Sascha Fauser; Marina Mesquida

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):2611.

ARVO Annual Meeting Abstract June 2024

IL-6 inhibition with vamikibart in patients with uveitic macular edema: phase 3 MEERKAT and SANDCAT trials

Eric B Suhler; Laura Steeples; Markus Elze; Lachlan Macgregor; David Silverman; Zdenka Haskova

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):2609.

ARVO Annual Meeting Abstract June 2023

A novel intravitreal anti-IL-6 monoclonal antibody for uveitic macular edema (UME): preliminary results from the phase 1 DOVETAIL study

Sumit Sharma; Eric Suhler; Phoebe Lin; Meike Pauly-Evers; Daniela Willen; Robbie Peck; Federica Storti; Simone Rauhut; Tatiana Gott; Benedicte Passemard; Lachlan Macgregor; Zdenka Haskova; David Silverman; Sascha Fauser; Marina Mesquida

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):5100.

ARVO Annual Meeting Abstract June 2023

Durable vision gains and greater fluid control with extended faricimab dosing vs aflibercept in patients with DME

Jennifer I Lim; Shih-Jen Chen; Nathan Steinle; Glenn J Jaffe; Bianca S Gerendas; Francis Abreu; Acner Camino; Kara Gibson; Nitin Jain; Eugene Shildkrot; Audrey Souverain; Yannan Tang; Jeffrey Willis; Zdenka Haskova

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):2815.

ARVO Annual Meeting Abstract June 2023

Baseline characteristics associated with the first year treatment interval of intravitreal faricimab in diabetic macular edema (DME).

Parth Arvind Shah; Yannan Tang; Neala Rafijah; Zdenka Haskova; Jeffrey Ryuta Willis; Aachal Kotecha

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):2697.

ARVO Annual Meeting Abstract June 2023

Morph-interpolation visualizations of the effect of monthly intravitreal injections of faricimab 6.0 mg in patients with diabetic macular edema from the BOULEVARD trial

Carl Glittenberg; Andreas Maunz; Zdenka Haskova; Aachal Kotecha; Nitin Jain; Michael Singer

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):2635.

ARVO Annual Meeting Abstract June 2023

Faricimab reduces macular leakage vs aflibercept in patients with DME

Roger A. Goldberg; Anton Kolomeyer; Eric Nudleman; Karl Csaky; Jeffrey Willis; Kara Gibson; Tracey Wang; Zdenka Haskova; Eugene Shildkrot; Manuel Amador; Florie Mar

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):2816.

ARVO Annual Meeting Abstract June 2023

Faster time to retinal fluid control with faricimab versus aflibercept in patients with DME in the phase 3 YOSEMITE/RHINE trials

Andreas Pollreisz; Acner Camino; Kara Gibson; Florie Mar; Eugene Shildkrot; Yannan Tang; Jeffrey Willis; Zdenka Haskova

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):2817.

ARVO Annual Meeting Abstract June 2022

Anti-VEGF for diabetic retinopathy treatment: systematic review of randomized controlled trials

Laura Le; Paul Latkany; Nikisha Kothari; Nathan Scott; Marianeli Rodriguez; Nimesh Patel; Nicolas Yannuzzi; Zdenka Haskova; Natalia Callaway

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):571 – A0136.

ARVO Annual Meeting Abstract June 2022

Angiopoietin-2 (Ang-2) signaling and vascular stability with faricimab in diabetic macular edema (DME)

Yasha Modi; Karl Csaky; Veeral Sheth; Jeffrey Willis; Zdenka Haskova; Peter Westenskow

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):2522 – F0248.

ARVO Annual Meeting Abstract June 2022

Personalized treatment interval (PTI) dosing dynamics over 2 years in the phase 3 YOSEMITE and RHINE trials of faricimab in diabetic macular edema

Caroline R Baumal; John Kitchens; Glenn Jaffe; Bianca S Gerendas; Francis Abreu; Kemal Asik; Acner Camino; Nitin Jain; Zdenka Haskova

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):3851.

ARVO Annual Meeting Abstract June 2022

Efficacy, durability, and safety of faricimab in diabetic macular edema: 2-year results from the phase 3 YOSEMITE and RHINE trials

Jennifer I Lim; John A Wells; David Aaron Eichenbaum; Carl J Danzig; Kemal Asik; Zdenka Haskova; Shaun Mohan; David Silverman; Yannan Tang; Hugh Lin

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):3850.

ARVO Annual Meeting Abstract June 2021

Clinical trial versus real-world outcomes with anti-VEGF therapy for branch and central retinal vein occlusion

Carl J Danzig; Steven Blotner; Verena Steffen; Zdenka Haskova

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):3174.

ARVO Annual Meeting Abstract June 2021

Prediction of ranibizumab injection frequency in patients with macular edema due to retinal vein occlusion during as-needed dosing period of BRAVO and CRUISE Phase 3 trials

Yun Li; Verena Steffen; Fethallah Benmansour; Michel Friesenhahn; Zdenka Haskova

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):127.

ARVO Annual Meeting Abstract June 2021

Efficacy and safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD): Results from open-label extension periods of SAkuraSky and SAkuraStar

Zdenka Haskova; Benjamin Greenberg; Jeffrey Bennett; Brian G. Weinshenker; Anthony Traboulsee; Michael R. Yeaman; Kristina Weber; Kathleen Blondeau; H-Christian von Büdingen; Daniela Stokmaier; Gaëlle Klingelschmitt

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):3475.

ARVO Annual Meeting Abstract June 2021

DR progression analyses and its association with race and diabetes type in real-world patients with diabetes in the US

Geeta Lalwani; Charles Clifton Wykoff; Jayla Briggs; 4. Chin-Yu Lin; Verena Steffen; Zdenka Haskova

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):1096.

ARVO Annual Meeting Abstract June 2021

Design and rationale of the YOSEMITE and RHINE trials: two phase 3 studies of faricimab in patients with diabetic macular edema

Nicole Eter; Jeffrey R Willis; Carlos Quezada Ruiz; Francis Abreu; Hugh Lin; David Silverman; Jane Ives; Karen Basu; Zdenka Haskova; Kemal Asik

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):1043.

ARVO Annual Meeting Abstract June 2021

Efficacy, durability, and safety of faricimab in diabetic macular edema (DME): one-year results from the phase 3 YOSEMITE and RHINE trials

John A Wells; Charles Clifton Wykoff; Jeffrey R Willis; Zdenka Haskova; Hugh Lin; David Silverman; Anthony P Adamis; Jane Ives; Francis Abreu; Karen Basu; Ramin Tadayoni

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):1037.

ARVO Annual Meeting Abstract June 2020

Clinical Effects of Blocking Ang-2 and VEGF with Faricimab in the Phase 2 STAIRWAY Trial

Carl J Danzig; Hugh Lin; Pascal Guibord; David Silverman; Carlos Quezada Ruiz; Ivo Stoilov; Zdenka Haskova

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):1160.

1 2

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

Clinically Meaningful Change Estimates for the National Eye Institute Visual Function Questionnaire-25 in Patients With Diabetic Macular Edema

Intravitreal interleukin-6 inhibition with vamikibart in sarcoidosis-associated uveitis

IL-6 inhibition with vamikibart in patients with uveitic macular edema: phase 3 MEERKAT and SANDCAT trials

A novel intravitreal anti-IL-6 monoclonal antibody for uveitic macular edema (UME): preliminary results from the phase 1 DOVETAIL study

Durable vision gains and greater fluid control with extended faricimab dosing vs aflibercept in patients with DME

Baseline characteristics associated with the first year treatment interval of intravitreal faricimab in diabetic macular edema (DME).

Morph-interpolation visualizations of the effect of monthly intravitreal injections of faricimab 6.0 mg in patients with diabetic macular edema from the BOULEVARD trial

Faricimab reduces macular leakage vs aflibercept in patients with DME

Faster time to retinal fluid control with faricimab versus aflibercept in patients with DME in the phase 3 YOSEMITE/RHINE trials

Anti-VEGF for diabetic retinopathy treatment: systematic review of randomized controlled trials

Angiopoietin-2 (Ang-2) signaling and vascular stability with faricimab in diabetic macular edema (DME)

Personalized treatment interval (PTI) dosing dynamics over 2 years in the phase 3 YOSEMITE and RHINE trials of faricimab in diabetic macular edema

Efficacy, durability, and safety of faricimab in diabetic macular edema: 2-year results from the phase 3 YOSEMITE and RHINE trials

Clinical trial versus real-world outcomes with anti-VEGF therapy for branch and central retinal vein occlusion

Prediction of ranibizumab injection frequency in patients with macular edema due to retinal vein occlusion during as-needed dosing period of BRAVO and CRUISE Phase 3 trials

Efficacy and safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD): Results from open-label extension periods of SAkuraSky and SAkuraStar

DR progression analyses and its association with race and diabetes type in real-world patients with diabetes in the US

Design and rationale of the YOSEMITE and RHINE trials: two phase 3 studies of faricimab in patients with diabetic macular edema

Efficacy, durability, and safety of faricimab in diabetic macular edema (DME): one-year results from the phase 3 YOSEMITE and RHINE trials

Clinical Effects of Blocking Ang-2 and VEGF with Faricimab in the Phase 2 STAIRWAY Trial

To View More...

You must be signed into an individual account to use this feature.